-1 	|BT| (NP (NP (NP (JJ Inhibitory) (NN effect) (JJ oleanolic) (NN acid) (JJ hepatocellular) (NN carcinoma)) (PP (IN via) (NP (NP (JJ ERK-p53-mediated) (NN cell) (NN cycle) (NN arrest)) (NP (JJ mitochondrial-dependent) (NN apoptosis)))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 104:C04.557.470.200.025.255 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 772:D02.455.849.919.530.733 773:G04.299.134.109|ES| 19:1 75:1 89:1 94:1 303:1 304:1 596:1 601:1 602:1 1275:1 2713:1 2714:1 2715:1 2716:1
-1 	|BT| (NP (NP (JJ Inhibitory) (NN effect) (NN silibinin) (JJ azoxymethane-induced) (NN colon) (NN tumorigenesis) (NN A/J) (NN mouse))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080|ES| 19:1 52:1 75:1 78:1 113:1 2533:1 2534:1 2635:1 2713:1
-1 	|BT| (S (NP (NN K-Ras) (NN mutation) (NN treatment) (NN outcome) (JJ colorectal) (NN cancer) (NN patient)) (VP (VBG receiving) (NP (JJ exclusive) (NN fluoropyrimidine) (NN therapy)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 18:G05.365.590 50:M01.643 52:E02 164:E01.789.800|ES| 13:1 17:1 18:1 19:1 34:1 120:1 130:1 546:1 547:1 548:1 549:1 550:1
-1 	|BT| (S (NP (NP (JJ Kruppel-like) (NN factor) (CD 9)) (PRN (-LRB- -LRB-) (NP (NN KLF9)) (-RRB- -RRB-))) (VP (VBZ prevents) (NP (JJ colorectal) (NN cancer) (NN inhibition) (JJ interferon-related) (NN signaling)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 43:F01.145.544 69:G02.111.087.800 617:D12.644.276.374.440 774:D12.776.124.125.375|ES| 10:1 14:1 17:1 18:1 19:1 103:1 185:1 195:1 318:1 703:1 2717:1 2718:1 2719:1
-1 	|BT| (S (NP (NN Latexin)) (VP (VBP exhibit) (NP (NN tumor) (NN suppressor) (JJ potential) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|104:C04.557.470.200.025.255 175:J01.897.280.500.269 206:G05.360.340.024.340.375.249|ES| 7:1 19:1 303:1 304:1 587:1 700:1 827:1 2720:1
-1 	|BT| (S (NP (NN Liver) (NN cell) (NN proliferation)) (VP (VBD increased) (ADVP (RB significantly)) (NP (NP (NN liver) (NN tumor) (JJ tamoxifen-treated) (NN rat)) (NP (ADJP (CD 12) (NN month)) (NN treatment) (NN recovery) (NN period))))) |ET| |BS|52:E02 183:G04.299.233.750 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 640:D02.455.426.559.389.150.700.900 775:E02.760.058 776:G01.910.645|ES| 7:1 19:1 47:1 94:1 124:1 299:1 546:1 836:1 849:1 1120:1 2721:1 2722:1 2723:1 2724:1 2725:1
-1 	|BT| (S (S (NP (JJ Liver-specific) (NN deletion) (NN prohibitin) (CD 1)) (VP (VBP result) (NP (JJ spontaneous) (NN liver) (NN injury)))) (, ,) (NP (NP (NN fibrosis)) (, ,) (NP (JJ hepatocellular) (NN carcinoma) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 104:C04.557.470.200.025.255 242:A03.620 306:G05.355.600.800 691:C23.550.355|ES| 2:1 19:1 52:1 98:1 101:1 283:1 303:1 304:1 836:1 949:1 1059:1 2416:1 2726:1 2727:1
-1 	|BT| (S (NP (NN Loss) (NN Dicer)) (ADVP (RB primarily)) (VP (VBZ impairs) (SBAR (S (NP (NN hepatocyte) (NN survival)) (VP (VBP promote) (NP (NN hepatocarcinogenesis) (NN cooperation) (JJ additional) (JJ oncogenic) (NN stimulus))))))) |ET| |BS|96:I03.784 262:A11.436.348 279:D27.888.569.100|ES| 19:1 274:1 679:1 900:1 953:1 980:1 1788:1 1909:1 1960:1 1970:1 2728:1 2729:1 2730:1
-1 	|BT| (S (NP (NN Loss) (NN metallothionein)) (VP (VBZ predisposes) (NP (NN mouse) (JJ diethylnitrosamine-induced) (NN hepatocarcinogenesis) (VBG activating) (NN NF-kappaB) (NN target) (NN gene)))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 210:D12.776.260.600 554:D02.654.442.200 777:D12.776.556.670|ES| 9:1 19:1 52:1 160:1 714:1 900:1 1788:1 1948:1 1958:1 2731:1 2732:1
-1 	|BT| (S (NP (NNP Lycopene) (JJ active) (JJ chemopreventive) (NN agent) (NN offer) (NN protection) (JJ DEN-induced) (NN hepatocarcinogenesis)) (VP (VBG inhibiting) (NP (NN NF-kappaB) (NN mTOR) (NN pathway)))) |ET| |BS|122:C14.280.383 210:D12.776.260.600|ES| 19:1 197:1 383:1 714:1 728:1 880:1 900:1 1042:1 1946:1 2733:1 2734:1 2735:1 2736:1
-1 	|BT| (S (NP (NN Magnolol)) (VP (MD could) (ADVP (RB potentially)) (NP (JJ safe) (JJ potent) (JJ anticarcinogenic) (NN agent) (NN skin) (NN cancer)))) |ET| |BS|778:D27.505.954.444|ES| 18:1 19:1 22:1 333:1 728:1 773:1 908:1 2312:1 2319:1 2737:1
-1 	|BT| (S (NP (NN Melatonin)) (VP (VBD improved) (SBAR (S (NP (NN survival) (NN rate)) (VP (ADVP (RB successfully)) (VBD attenuated) (NP (NN liver) (NN injury))))) (, ,) (VP (VBN shown) (NP (NN histopathology))) (, ,) (VP (VBD decreased) (NP (NP (NN level) (NN serum) (NN transaminase)) (NP (VBN reduced) (NN expression) (JJ placental) (NN glutathione) (NN S-transferase)))))) |ET| |BS|242:A03.620 707:D03.438.473.914.481 779:E05.318.308.985.550.900 780:D08.811.913.225.500 781:D08.811.913.477.700 782:A12.207.152.846 783:A16.710|ES| 2:1 19:1 41:1 115:1 202:1 237:1 249:1 274:1 452:1 808:1 836:1 2410:1 2416:1 2738:1 2739:1 2740:1 2741:1 2742:1 2743:1 2744:1 2745:1
-1 	|BT| (S (NP (NN Metformin)) (VP (VBZ inhibits) (NP (JJ early) (NN stage) (JJ diethylnitrosamineinduced) (NN hepatocarcinogenesis) (NN rat)))) |ET| |BS|122:C14.280.383 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 784:D02.078.370.141.450|ES| 19:1 615:1 849:1 900:1 1128:1 1129:1 2746:1 2747:1
-1 	|BT| (NP (NP (NP (NN METHODOLOGY/PRINCIPAL) (NNS FINDINGS)) (: :) (NP (NP (JJ Pancreatic) (NN cancer) (NN cell) (NN line)) (VP (VBN treated) (NP (NN resveratrol)))))) |ET| |BS|52:E02 94:A11.251.210|ES| 18:1 19:1 94:1 104:1 264:1 1099:1 1213:1 1712:1 2748:1 2749:1
-1 	|BT| (NP (NP (NNS METHODS) (: :)) (NP (NP (JJ UVB-induced) (NN skin) (NN carcinogenesis) (NN model) (NN SKH-1) (NN mouse)) (VP (VBN used) (S (VP (VBG determining) (NP (JJ preventive) (NN effect) (NN magnolol) (NN skin) (NN cancer) (NN development))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 168:E05.581 785:A17.815|ES| 18:1 19:1 35:1 52:1 72:1 75:1 104:1 207:1 476:1 565:1 1883:1 2319:1 2526:1 2750:1 2751:1 2752:1
-1 	|BT| (S (NP (NN Methyl) (NN antcinate) (NN A) (NN Antrodia) (NN camphorata)) (VP (VBZ induces) (NP (NP (NN apoptosis) (JJ human) (NN liver) (NN cancer) (NN cell) (JJ oxidant-mediated) (NN cofilin)) (: -) (NP (JJ Bax-triggered) (JJ mitochondrial) (NN pathway))))) |ET| |BS|39:G04.299.139.160 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 342:D12.644.360.075.718.400 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 573:N05.715.350.200.650 786:B01.300.179.120.174.070 787:D27.720.642|ES| 18:1 19:1 36:1 69:1 89:1 94:1 214:1 383:1 836:1 2004:1 2753:1 2754:1 2755:1 2756:1 2757:1 2758:1 2759:1
-1 	|BT| (NP (NP (NN Modulation) (NN energy) (JJ metabolic) (NN enzyme) (NN expression) (JJ N-nitrosodiethylamine-mediated) (NN hepatocarcinogenesis) (JJ Chinese) (NN herb)) (, ,) (NP (NNP Huqi) (NNP San))) |ET| |BS|554:D02.654.442.200 730:D08.811 788:H01.158.273.118.598.500|ES| 2:1 19:1 115:1 900:1 2006:1 2388:1 2760:1 2761:1 2762:1 2763:1 2764:1 2765:1 2766:1
-1 	|BT| (FRAG (ADVP (RBR More) (RB importantly)) (, ,) (NP (NP (NN EPLE)) (VBN hampered) (NN tumor) (NN development) (NN CRC) (NN xenograft) (NN model))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 92:E04.936.764 93:A01.941.875|ES| 2:1 7:1 19:1 35:1 72:1 245:1 265:1 2489:1 2767:1 2768:1 2769:1
-1 	|BT| (S (ADVP (RB Moreover)) (, ,) (S (VP (VBG using) (NP (NP (NN mouse) (NN xenograft) (NN model)) (, ,) (NP (NN show) (NN treatment) (JJ specific) (NNP PPOX) (NN inhibitor) (NN acifluorfen))))) (ADVP (RB significantly)) (VP (VBD reduced) (NP (NP (NP (NP (NN growth) (CD three) (CD seven)) (PRN (-LRB- -LRB-) (NP (CD 42.8) (NN %)) (-RRB- -RRB-))) (NN colon) (NN cancer) (NN line)) (NP (VBN investigated))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 45:G07.700.320.249 52:E02 92:E04.936.764 93:A01.941.875|ES| 2:1 10:1 14:1 18:1 19:1 52:1 72:1 102:1 113:1 124:1 264:1 265:1 350:1 369:1 380:1 403:1 429:1 452:1 482:1 540:1 546:1 622:1 1733:1 2770:1 2771:1 2772:1
-1 	|BT| (S (NP (NP (NNP Myrtenal)) (, ,) (NP (JJ natural) (NN monoterpene)) (, ,)) (VP (VBZ down-regulates) (SBAR (S (NP (NN TNF-alpha) (NN expression)) (VP (VBZ suppresses) (NP (JJ carcinogen-induced) (JJ hepatocellular) (NN carcinoma) (NN rat))))))) |ET| |BS|104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 279:D27.888.569.100 351:A17.360 758:D02.455.849.575 789:D12.644.276.374.500.800 790:D12.644.276.374.750|ES| 2:1 19:1 115:1 303:1 304:1 686:1 849:1 2333:1 2421:1 2683:1 2773:1 2774:1 2775:1
-1 	|BT| (S (NP (NN N-acetyl-L-cysteine)) (VP (VBD blocked) (SBAR (S (NP (NN EGFR) (NN activation)) (VP (VBD reduced) (NP (JJ N-nitrosodiethylamine-initiated) (NN hepatocarcinogenesis) (NN level) (NNP Cre-Ctrl) (NN mouse))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 122:C14.280.383 554:D02.654.442.200 791:D02.886.030.230.259|ES| 19:1 52:1 187:1 225:1 249:1 452:1 900:1 2776:1 2777:1 2778:1 2779:1
-1 	|BT| (S (NP (JJ Natural) (NNS polyphenols)) (VP (VBP facilitate) (NP (NP (NN elimination) (NN HT-29) (JJ colorectal) (NN cancer) (NN xenograft) (NN chemoradiotherapy)) (: :) (NP (NP (NN Bcl-2)) (: -) (NP (NN superoxide) (NN dismutase) (JJ 2-dependent) (NN mechanism)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 54:G05.360.340.024.340.375.500.791.150 56:D02.455.426.559.389.657.715 59:E02.186.079 92:E04.936.764 93:A01.941.875 792:A11.251.210.190.475|ES| 17:1 18:1 19:1 104:1 146:1 147:1 154:1 156:1 162:1 265:1 1989:1 2780:1 2781:1 2782:1 2783:1 2784:1
-1 	|BT| (S (NP (JJ Natural) (NN product) (NN pectolinarigenin)) (VP (VBZ inhibits) (NP (NN osteosarcoma) (NN growth) (NN metastasis)) (PP (IN via) (NP (JJ SHP-1-mediated) (NN STAT3) (NN signaling) (NN inhibition))))) |ET| |BS|43:F01.145.544 45:G07.700.320.249 69:G02.111.087.800 82:D12.644.360.024.342.300 113:C04.697.650 122:C14.280.383 447:C04.557.450.565.575.650 793:D20.215|ES| 19:1 102:1 103:1 195:1 251:1 596:1 615:1 675:1 806:1 1562:1 2780:1 2785:1 2786:1
-1 	|BT| (S (NP (NN Nitidine) (NN chloride)) (VP (VBZ inhibits) (NP (NP (JJ hepatocellular) (NN carcinoma) (NN cell)) (NN growth)) (NP (FW vivo) (NN suppression) (NN JAK1/STAT3) (NN signaling) (NN pathway)))) |ET| |BS|41:A11 45:G07.700.320.249 69:G02.111.087.800 82:D12.644.360.024.342.300 104:C04.557.470.200.025.255 122:C14.280.383 126:G02.111.087.800 794:D08.811.913.696.620.682.725.124.100|ES| 19:1 94:1 102:1 195:1 303:1 304:1 378:1 383:1 615:1 2453:1 2787:1 2788:1 2789:1
-1 	|BT| (NP (NP (NP (JJ Nitric) (JJ oxide-releasing) (NN aspirin) (NN indomethacin) (JJ potent) (NN inhibitor) (NN colon) (NN cancer) (JJ azoxymethane-treated) (NN rat)) (: :) (NP (NN effect) (JJ molecular) (NN target)))) |ET| |BS|52:E02 132:D02.172.080 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 795:D03.438.473.420|ES| 18:1 19:1 22:1 75:1 104:1 113:1 160:1 161:1 380:1 849:1 2487:1 2790:1 2791:1 2792:1 2793:1
-1 	|BT| (NP (NP (JJ Non-steroidal) (JJ anti-inflammatory) (NN drug) (NN sulindac) (JJ promising) (NN chemoprevention) (NN agent) (NN colon) (NN cancer)) (, ,) (NP (JJ weak) (NN potency) (NN side) (NN effect) (NN limit) (NN use) (NN chemoprevention) (NN chemotherapy))) |ET| |BS|151:E02.319 251:D02.455.426.559.847.486.875 253:E02.319.162 796:D27.505.696.663.850.014.040.500|ES| 2:1 18:1 19:1 75:1 113:1 191:1 338:1 495:1 728:1 869:1 870:1 871:1 1517:1 1659:1 2794:1 2795:1 2796:1 2797:1
-1 	|BT| (S (S (ADVP (RB Notably)) (, ,) (NP (JJ adeno-XAF1) (NN treatment)) (ADVP (RB significantly)) (VP (VBD inhibited) (NP (NN tumor) (NN growth)) (, ,) (ADVP (NP (ADJP (RB strongly) (VBN enhanced)) (NN antitumor) (NN activity) (NN TRAIL) (JJ gastric) (NN cancer) (NN xenograft) (NN model)) (FW vivo)) (, ,) (NP (RB significantly) (JJ prolonged) (NN survival) (NN time) (JJ animal) (NN bearing) (NN tumor) (NN xenograft))))) |ET| |BS|8:C04 19:B01.050 45:G07.700.320.249 52:E02 92:E04.936.764 93:A01.941.875 96:I03.784 122:C14.280.383 322:G01.910 455:B01.050.150.900.649.147.890|ES| 2:1 7:1 18:1 19:1 46:1 72:1 86:1 102:1 124:1 265:1 274:1 365:1 378:1 385:1 399:1 546:1 635:1 1081:1 1584:1 1695:1 2244:1 2798:1 2799:1 2800:1
-1 	|BT| (S (ADVP (RB Notably)) (, ,) (NP (NN colon) (NN tumor) (NN prevention) (NN activity) (NN sulindac)) (VP (VP (VBN accompanied) (NP (NP (JJ marked) (NN induction) (JJ lymphoid) (NN aggregate)) (NP (JJ proximal) (JJ colonic) (JJ inflammatory) (NN mass) (NN lesion)))) (, ,) (VP (S (NP (JJ side) (NN effect)) (VP (VBN seen) (NP (JJR lesser) (NN degree) (NN celecoxib)))) (, ,) (NP (NN aspirin))))) |ET| |BS|51:C04.588.274.476.411.307.180 213:F02.830.816.964 251:D02.455.426.559.847.486.875 670:D02.455.426.559.389.657.410.595.176 684:D02.065.884.247 797:A10.549.600|ES| 2:1 7:1 19:1 75:1 113:1 399:1 677:1 724:1 736:1 869:1 871:1 1070:1 1131:1 1474:1 1967:1 2430:1 2487:1 2798:1 2801:1 2802:1 2803:1 2804:1 2805:1 2806:1 2807:1
-1 	|BT| (S (NP (JJ Nuclear) (NN Maspin) (NN expression)) (NP (ADJP (RB highly) (JJ predictive)) (NN 5-FU) (NN chemotherapy) (NN response) (NN patient)) (VP (VBD advanced) (NP (NN stage) (NN colon) (NN cancer)))) |ET| |BS|50:M01.643 151:E02.319 560:D03.383.742.698.875.404|ES| 18:1 19:1 113:1 115:1 120:1 494:1 495:1 533:1 626:1 997:1 1129:1 2308:1 2808:1 2809:1
-1 	|BT| (FRAG (PP (IN On) (NP (NN basis) (NN finding) (, ,) (NN development) (NN 2-aryl) (NN benzimidazole) (NN derivative))) (, ,) (NP (NP (JJ new) (NN class) (JJ multitarget) (JJ anticancer) (NN agent)) (, ,) (VP (VBD warranted) (VP (VBZ represents) (NP (NP (JJ novel) (NN strategy)) (VP (VBG improving) (NP (NN breast) (NN cancer) (NN treatment)))))))) |ET| |BS|52:E02 259:D12.776.395.240.150.500 660:D27.505.954.248 798:D03.438.103|ES| 2:1 18:1 19:1 23:1 35:1 546:1 712:1 728:1 891:1 927:1 1114:1 1140:1 1880:1 2363:1 2516:1 2810:1 2811:1 2812:1 2813:1 2814:1 2815:1 2816:1
-1 	|BT| (S (NP (ADJP (RB Orally) (VBN administered)) (NN lycopene)) (VP (VBZ attenuates) (NP (NP (JJ diethylnitrosamine-induced) (NN hepatocarcinogenesis) (NN rat)) (VP (VBG modulating) (NP (NP (NN Nrf-2)) (: /) (NP (NN HO-1) (NN Akt/mTOR) (NN pathway))))))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 378:D08.811.913.696.620.682.700.755 554:D02.654.442.200 799:D12.776.260.615.249 800:Z01.107.169.534|ES| 19:1 383:1 849:1 900:1 2336:1 2423:1 2435:1 2566:1 2732:1 2817:1 2818:1 2819:1
-1 	|BT| (S (NP (PRP$ Our) (NNS data)) (VP (VBD indicated) (SBAR (S (NP (NN nifuroxazide)) (VP (MD may) (ADVP (RB potentially)) (NP (JJ therapeutic) (NN agent) (NN growth) (NN metastasis) (NN breast) (NN cancer))))))) |ET| |BS|52:E02 113:C04.697.650|ES| 18:1 19:1 23:1 102:1 491:1 541:1 658:1 728:1 773:1 793:1 806:1 1541:1 2820:1
-1 	|BT| (S (NP (PRP$ Our) (NNS data)) (VP (VBD indicated) (NP (NP (NN silymarin) (JJ therapeutic) (NN effect)) (NP (JJ early) (NN stage) (NN liver) (NN damage))) (, ,) (S (VP (VBG reversing) (NP (NP (JJ fatty) (NN change)) (VP (VBG recovering) (NP (NN liver) (NN histopathology) (JJ dose-dependent) (NN manner)))))))) |ET| |BS|242:A03.620 801:D03.383.663.283.266.450.268.777|ES| 2:1 19:1 75:1 200:1 541:1 658:1 793:1 836:1 1128:1 1129:1 1541:1 1668:1 1848:1 2070:1 2740:1 2821:1 2822:1 2823:1 2824:1
-1 	|BT| (S (NP (PRP$ Our) (NNS data)) (ADVP (RB thus)) (VP (VBP establish) (SBAR (S (NP (NN EPLE) (JJ novel) (NN inhibitor) (NN Wnt) (NN signaling)) (VP (VBP hold) (NP (JJ great) (NN promise) (JJ potential) (NN candidate) (JJ preclinical) (NN evaluation) (NN CRC) (NN treatment))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 52:E02 69:G02.111.087.800 225:E05.337 259:D12.776.395.240.150.500|ES| 19:1 195:1 220:1 245:1 380:1 546:1 658:1 793:1 827:1 877:1 891:1 1243:1 1334:1 1494:1 2489:1 2503:1 2825:1 2826:1 2827:1
-1 	|BT| (S (NP (PRP$ Our) (NNS data) (NN pterostilbene)) (VP (VBG suppressing) (NP (NP (NN colon) (NN tumorigenesis)) (, ,) (NP (NN cell) (NN proliferation)) (NP (ADJP (RB well) (JJ key)) (JJ inflammatory) (NN marker))) (ADVP (FW vivo) (FW vitro)) (VP (VBP suggest) (NP (JJ potential) (NN use) (NN pterostilbene) (NN colon) (NN cancer) (NN prevention))))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 158:D23.101 183:G04.299.233.750|ES| 2:1 18:1 19:1 78:1 94:1 113:1 159:1 216:1 299:1 378:1 534:1 658:1 787:1 793:1 796:1 827:1 1474:1 1659:1 2250:1 2428:1 2430:1
-1 	|BT| (S (NP (PRP$ Our) (NN finding)) (ADVP (RB also)) (VP (VBD showed) (SBAR (S (NP (NP (JJ myrtenal) (NNS restrains) (NN liver) (NN cancer)) (VP (VBG preventing) (NP (NN DEN-PB)))) (VP (VBD induced) (NP (NN up-regulation) (NN TNF-alpha) (NN protein) (NN expression) (NN immunoblot))))))) |ET| |BS|7:D12.776 122:C14.280.383 142:I01.880.604 789:D12.644.276.374.500.800 790:D12.644.276.374.750 802:E05.478.566.320|ES| 4:1 5:1 18:1 19:1 115:1 132:1 412:1 658:1 836:1 896:1 927:1 1937:1 2682:1 2775:1 2828:1 2829:1 2830:1
-1 	|BT| (S (NP (PRP$ Our) (NN finding)) (VP (VBP suggest) (NP (NN rimonabant) (ADJP (JJ able) (S (VP (VBP inhibit) (NP (NP (JJ colorectal) (NN cancer) (NN cell) (NN growth) (JJ different) (NN stage) (NN colon) (NN cancer) (NN pathogenesis)) (VP (VBG inducing) (NP (JJ mitotic) (NN catastrophe) (NN vitro)))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 45:G07.700.320.249 122:C14.280.383 385:F02.784.629.131|ES| 17:1 18:1 19:1 94:1 102:1 113:1 216:1 414:1 501:1 658:1 720:1 796:1 927:1 1129:1 1370:1 1864:1 2831:1 2832:1 2833:1
-1 	|BT| (S (NP (PRP$ Our) (JJ present) (NN study)) (VP (VBP identify) (S (NP (NP (JJ chemopreventive) (JJ potential) (NN pterostilbene) (JJ colonic) (NN tumor) (NN formation)) (NN end) (NN point)) (VP (VB evaluate) (NP (JJ mechanistic) (NN action) (NN pterostilbene) (NN colon) (NN carcinogenesis)))))) |ET| |BS|20:G03.495 30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 46:A03.556.124.526.356 51:C04.588.274.476.411.307.180 225:E05.337 742:G03.787|ES| 7:1 19:1 43:1 113:1 131:1 207:1 658:1 677:1 827:1 832:1 890:1 1307:1 1890:1 1946:1 2013:1 2121:1 2428:1 2834:1
-1 	|BT| (S (NP (PRP$ Our) (JJ previous) (NN study)) (VP (VBD demonstrated) (SBAR (S (NP (NP (JJ garlic) (NN oil)) (PRN (-LRB- -LRB-) (NP (NN GO)) (-RRB- -RRB-))) (VP (MD could) (VP (VB prevent) (NP (JJ NDEA-induced) (NN hepatocarcinogenesis) (NN rat)) (, ,) (NP (NP (VBG underlying) (NN mechanism)) (VP (ADVP (RB fully)) (VBN understood))))))))) |ET| |BS|239:F02.463.188.357 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200|ES| 2:1 10:1 14:1 19:1 131:1 162:1 435:1 658:1 733:1 849:1 889:1 900:1 908:1 979:1 1175:1 1819:1 2614:1 2835:1 2836:1 2837:1
-1 	|BT| (S (PRP$ Our) (VP (VBP result) (ADVP (RB clearly)) (VP (VBP indicate) (SBAR (S (NP (JJ sulfated) (NN polysaccharide) (NNP U.) (NN lactuca)) (VP (VBD exert) (NP (JJ marked) (NN chemoprevention) (JJ DENA-initiated) (NN hepatocarcinogenesis) (NN inhibition) (JJ abnormal) (NN cell) (NN proliferation) (NN induction) (NN apoptosis)))))))) |ET| |BS|39:G04.299.139.160 43:F01.145.544 183:G04.299.233.750 253:E02.319.162 554:D02.654.442.200 803:D01.248.497.158.845 804:D09.698|ES| 19:1 89:1 94:1 101:1 103:1 299:1 658:1 736:1 870:1 900:1 1229:1 1479:1 2802:1 2838:1 2839:1 2840:1 2841:1 2842:1 2843:1 2844:1
-1 	|BT| (NP (NP (PRP$ Our) (VP (VBP result) (VP (VBP demonstrate)) (, ,) (NP (ADVP (JJ first) (NN time)) (, ,) (NP (NP (NP (ADJP (NN elaiophylin) (JJ novel)) (NN autophagy) (NN inhibitor)) (, ,) (NP (NP (JJ significant) (NN antitumor) (NN efficacy)) (JJ single) (NP (NN agent) (NN combination) (JJ human) (JJ ovarian) (NN cancer) (NN cell)))) (, ,) (VP (VBG establishing) (NP (JJ potential) (NN treatment) (JJ ovarian) (NN cancer) (NN compound)))))))) |ET| |BS|41:A11 52:E02 55:B01.050.150.900.649.801.400.112.400.400 259:D12.776.395.240.150.500 322:G01.910 390:G04.299.139.399 660:D27.505.954.248 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725|ES| 2:1 18:1 19:1 36:1 94:1 101:1 135:1 380:1 502:1 530:1 546:1 658:1 728:1 816:1 827:1 891:1 1081:1 1317:1 1763:1 2244:1 2304:1 2433:1 2845:1 2846:1 2847:1
-1 	|BT| (S (NP (PRP$ Our) (VBP result)) (VP (VBP indicate) (SBAR (S (NP (NNP Lrat) (NNP KO) (NN mouse)) (NP (DT le) (JJ susceptible) (JJ DEN-induced) (NN hepatocarcinogenesis)) (ADVP (RB due)) (VP (VBD increased) (NP (ADJP (NP (NN retinoid) (NN signaling)) (JJR higher)) (NN expression) (NN p21)) (, ,) (SBAR (S (NP (NP (VBN accompanied) (JJ altered) (JJ hepatic) (NN level)) (JJ DEN-activating) (NN enzyme) (NNP MGMT) (NNP Lrat) (NNP KO) (NN mouse)) (ADVP (RB also)) (VP (VBP contribute) (SBAR (S (NP (VBN decreased) (NN cancer) (NN initiation)) (VP (VBD suppressed) (NP (NN liver) (NN tumor) (NN development))))))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 69:G02.111.087.800 515:C04.588.274.623 649:E01.370.225.124.200 711:D02.455.326.271.665.202.495 807:D08.811.913.555.500.800.650|ES| 2:1 5:1 7:1 18:1 19:1 35:1 47:1 52:1 101:1 115:1 170:1 195:1 202:1 249:1 307:1 450:1 637:1 658:1 693:1 836:1 838:1 899:1 900:1 1135:1 1479:1 2388:1 2573:1 2735:1 2801:1 2848:1 2849:1 2850:1 2851:1 2852:1 2853:1
-1 	|BT| (S (NP (PRP$ Our) (VBP result)) (VP (VBP indicate) (SBAR (S (NP (NP (NN administration) (NN resveratrol)) (UCP (CC either) (NP (JJ early) (JJ advanced) (NN stage) (NN hepatocarcinogenesis)) (ADJP (RB equally) (JJ effective)))) (VP (VBZ involves) (NP (NP (NN activation)) (NP (JJ apoptotic) (NN pathway) (NN male) (NNP Wistar) (NN rat)))))))) |ET| |BS|39:G04.299.139.160 723:B01.050.150.900.649.865.635.505.700.900|ES| 19:1 39:1 101:1 225:1 383:1 658:1 849:1 900:1 997:1 1128:1 1129:1 1402:1 1479:1 1639:1 1673:1 1712:1 2223:1 2575:1 2603:1 2854:1
-1 	|BT| (NP (NP (PRP$ Our) (VP (VBP result) (NP (NN show) (NN enzastaurin) (JJ effective) (JJ chemopreventive) (NN agent) (NN mouse) (NN model) (JJ sporadic) (NN colon) (NN cancer)) (SBAR (S (ADVP (RB significantly)) (VP (VBZ reduces) (NP (NP (NN tumor) (NN initiation) (NN progression)) (VP (VBG inhibiting) (NP (NN expression) (JJ proproliferative) (NN gene)))))))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 16:C23.550.291.656 122:C14.280.383 155:G05.355.310|ES| 7:1 9:1 18:1 19:1 48:1 52:1 72:1 101:1 113:1 115:1 124:1 142:1 429:1 637:1 658:1 725:1 728:1 880:1 1639:1 1946:1 2855:1 2856:1
-1 	|BT| (S (NP (PRP$ Our) (NN result)) (VP (VBD showed) (NP (NN cimetidine) (VBG inhibiting) (NN effect) (NN hepatocarcinogenesis)))) |ET| |BS|12:Z01.542.049 122:C14.280.383 808:D02.078.370.200|ES| 19:1 75:1 101:1 132:1 658:1 880:1 900:1 2857:1
-1 	|BT| (S (NP (PRP$ Our) (NN study)) (VP (VBZ demonstrates) (NP (NP (NN inhibition) (NN cell) (NN proliferation) (NN regulation)) (SBAR (S (NP (JJ inflammatory) (NN marker)) (VP (MD may) (, ,) (ADVP (JJS least) (NN part)) (, ,) (S (VP (VBG underlying) (NP (NN mechanism) (JJ related) (NN liver) (NN tumor) (NN inhibition) (NN diosmin)))))))))) |ET| |BS|41:A11 43:F01.145.544 85:G02.111.087.225 158:D23.101 183:G04.299.233.750 515:C04.588.274.623 715:D03.383.663.283.266.450.260.222|ES| 2:1 7:1 19:1 94:1 103:1 131:1 162:1 299:1 419:1 435:1 438:1 451:1 491:1 534:1 658:1 836:1 1331:1 2430:1 2541:1 2695:1
-1 	|BT| (S (NP (JJ Overall) (NN finding)) (VP (VBP substantiate) (SBAR (S (NP (NN artesunate)) (VP (VBZ promotes) (SBAR (S (NP (JJ anti-tumour) (, ,) (JJ anti-proliferation) (NN apoptosis) (NN nitrosodiethylamine)) (VP (VBD mediated) (NP (JJ hepatocellular) (NN carcinoma)))))))))) |ET| |BS|8:C04 39:G04.299.139.160 104:C04.557.470.200.025.255 554:D02.654.442.200 696:V02.270.500|ES| 2:1 19:1 89:1 298:1 303:1 304:1 437:1 927:1 2434:1 2858:1 2859:1 2860:1 2861:1 2862:1
-1 	|BT| (SINV (S (NP (JJ Overall) (NN analysis)) (VP (VBD indicated) (SBAR (S (NP (NN pterostilbene)) (VP (VBD reduced) (NP (NN colon) (NN tumor) (NN multiplicity) (JJ non-invasive) (NN adenocarcinoma))))))) (, ,) (VP (VBD lowered) (S (VP (VBG proliferating) (NP (NN cell) (JJ nuclear) (NN antigen))))) (VP (VBD downregulated) (NP (NN expression) (NN beta-catenin) (NN cyclin) (NN D1)))) |ET| |BS|23:D12.776.091.249 51:C04.588.274.476.411.307.180 84:C04.557.470.200.025 215:D12.644.360.262.150.100 696:V02.270.500 768:D12.776.660.740|ES| 2:1 7:1 19:1 60:1 94:1 113:1 115:1 255:1 426:1 452:1 661:1 743:1 744:1 1030:1 1256:1 1361:1 1541:1 2428:1 2858:1 2863:1 2864:1 2865:1
-1 	|BT| (S (ADVP (RB Overall)) (, ,) (VP (VBP result) (NP (NN support) (JJ translational) (JJ potential) (NN silibinin) (JJ colorectal) (NN cancer) (NN chemoprevention)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 145:G02.111.087.675.871 253:E02.319.162 696:V02.270.500 809:L01.178.682.920|ES| 2:1 17:1 18:1 19:1 101:1 827:1 870:1 1364:1 2635:1 2858:1 2866:1
-1 	|BT| (S (NP (NN Overexpression) (NN Klotho)) (VP (VBZ suppresses) (SBAR (S (NP (NN liver) (NN cancer) (NN progression)) (VP (VBZ induces) (S (NP (NN cell) (NN apoptosis)) (ADVP (RB negatively)) (VP (VBG regulating) (NP (JJ wnt/beta-catenin) (NN signaling) (NN pathway))))))))) |ET| |BS|16:C23.550.291.656 39:G04.299.139.160 41:A11 105:G02.149.115.800.925|ES| 18:1 19:1 48:1 89:1 94:1 195:1 214:1 383:1 668:1 686:1 836:1 2867:1 2868:1 2869:1 2870:1
-1 	|BT| (S (NP (NN Peroxisome) (JJ proliferator-activated) (NN receptor-gamma)) (VP (VBZ contributes) (NP (JJ inhibitory) (NN effect) (NN Embelin) (NN colon) (NN carcinogenesis)))) |ET| |BS|33:C04.697.098 46:A03.556.124.526.356 719:D12.776.826.239.588|ES| 19:1 75:1 113:1 207:1 845:1 1800:1 1801:1 2429:1 2587:1 2871:1
-1 	|BT| (NP (NP (NP (JJ Pharmacogenetic) (NN approach) (NN capecitabine) (NN 5-fluorouracil) (NN selection)) (SBAR (S (NP (VBN combined) (NN oxaliplatin) (JJ first-line) (NN chemotherapy)) (VP (VBD advanced) (NP (JJ colorectal) (NN cancer))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 151:E02.319 375:Z01.639.100 560:D03.383.742.698.875.404 810:D03.383.742.680.245.500.425 811:H01.158.273.343.750 812:G05.355.800|ES| 17:1 18:1 19:1 164:1 495:1 911:1 997:1 2307:1 2490:1 2543:1 2872:1 2873:1 2874:1
-1 	|BT| (S (NP (NN Phyllanthus) (NN urinaria)) (VP (VBZ ameliorates) (NP (NN severity) (JJ nutritional) (FW steatohepatitis) (FW vitro) (FW vivo)))) |ET| |BS|508:C06.552.241 813:B01.650.940.800.575.100.350.622|ES| 19:1 216:1 378:1 1473:1 1791:1 2875:1 2876:1 2877:1 2878:1
-1 	|BT| (S (NP (NN Polyenephosphatidylcholine)) (VP (VBZ prevents) (NP (NP (JJ alcoholic) (NN liver) (NN disease) (NN PPARalpha-null) (NN mouse) (NN attenuation) (NN increase)) (JJ oxidative) (NN stress)))) |ET| |BS|29:B01.050.050.136.500.500 536:D12.776.826.239.500 716:G03.495.710 814:C06.552.645|ES| 19:1 40:1 52:1 836:1 998:1 2522:1 2583:1 2718:1 2879:1 2880:1 2881:1 2882:1
-1 	|BT| (S (NP (NP (NP (JJ Polyinosinic-polycytidylic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN Poly) (NN I) (: :) (NN C)) (-RRB- -RRB-))) (NN IFN-gamma) (NN treatment)) (VP (VBD inhibited) (NP (NN liver) (NN fibrosis) (JJ pair-fed) (JJ ethanol-fed) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 52:E02 122:C14.280.383 663:C16.320.565.398.500.330.500 676:C06.552.630 751:D02.033.375 815:D13.695.578.550.560.600 816:G01.358.500.505.300|ES| 10:1 14:1 19:1 52:1 104:1 365:1 546:1 836:1 949:1 1275:1 1955:1 2350:1 2883:1 2884:1 2885:1 2886:1 2887:1
-1 	|BT| (NP (NP (NP (NP (NP (NP (NN PPARgamma)) (PRN (-LRB- -LRB-) (CC +) (: /) (: -))) (-RRB- -RRB-) (NN mouse) (JJ susceptible) (JJ DMH-induced) (NN colon) (NN carcinogenesis) (NN PPARgamma)) (PRN (-LRB- -LRB-) (CC +) (: /) (CC +) (-RRB- -RRB-))) (NP (NN mouse))) (, ,) (S (NP (NN embelin)) (ADVP (RB significantly)) (VP (VBD reduced) (NP (NP (NP (NN incidence) (NN colon) (NN cancer) (NN PPARgamma)) (PRN (-LRB- -LRB-) (NP (NP (CC +) (: /) (CC +) (-RRB- -RRB-) (NN mouse) (NN PPARgamma)) (PRN (-LRB- -LRB-) (CC +) (: /) (: -))) (-RRB- -RRB-))) (NN mouse))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 434:E05.318.308.985.525.375 719:D12.776.826.239.588|ES| 2:1 10:1 14:1 18:1 19:1 44:1 51:1 52:1 113:1 124:1 207:1 452:1 899:1 1511:1 2588:1 2888:1 2889:1
-1 	|BT| (S (NP (NNP Pravastatin)) (VP (VBZ reduces) (NP (NN lung) (NN metastasis) (NN rat) (JJ hepatocellular) (NN carcinoma)) (PP (IN via) (NP (VBN coordinated) (NN decrease) (NN MMP) (NN expression) (NN activity))))) |ET| |BS|104:C04.557.470.200.025.255 113:C04.697.650 182:A04.411 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 817:D02.455.426.559.847.638.930 818:D08.811.277.656.300.480.525|ES| 19:1 115:1 142:1 295:1 303:1 304:1 328:1 399:1 596:1 806:1 849:1 2890:1 2891:1 2892:1
-1 	|BT| (S (NP (JJ Preclinical) (JJ clinical) (NN investigation)) (VP (VBP demonstrate) (SBAR (S (NP (NN aspirin)) (VP (VBP inhibit) (NP (NP (JJ several) (NN type) (NN cancer) (JJ colorectal) (NN adenoma) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))))))) |ET| |BS|17:C04.557.470.035 104:C04.557.470.200.025.255 122:C14.280.383 225:E05.337 670:D02.455.426.559.389.657.410.595.176|ES| 10:1 14:1 17:1 18:1 19:1 42:1 84:1 262:1 303:1 304:1 441:1 502:1 543:1 1370:1 1497:1 2487:1 2893:1
-1 	|BT| (S (NP (NP (JJ Pre-operative) (NN 5-fluorouracil)) (PRN (-LRB- -LRB-) (NP (NN 5-FU)) (-RRB- -RRB-))) (: -) (NP (VBN based) (NN chemoradiotherapy)) (ADVP (RB locally)) (VP (VBD advanced) (SBAR (S (NP (NP (JJ rectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN UICC-II/III)) (-RRB- -RRB-))) (VP (MD may) (ADVP (RB significantly)) (VP (VB reduce) (NP (JJ local) (NN tumour) (NN mass)))))))) |ET| |BS|8:C04 59:E02.186.079 333:D01.045 560:D03.383.742.698.875.404|ES| 10:1 14:1 18:1 19:1 124:1 491:1 997:1 1011:1 1985:1 1986:1 1989:1 2307:1 2308:1 2361:1 2804:1 2894:1 2895:1 2896:1 2897:1
-1 	|BT| (NP (NP (NNP Prevention) (NN rat) (NN liver) (NN fibrosis) (NN carcinogenesis) (NN coffee) (NN caffeine))) |ET| |BS|33:C04.697.098 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 652:D20.215.784.249 676:C06.552.630 819:D03.132.960.175|ES| 19:1 207:1 836:1 849:1 949:1 2386:1 2898:1 2899:1
-1 	|BT| (NP (NP (JJ Previous) (NN study)) (VP (VBN shown) (S (NP (NN decorin) (NN expression)) (VP (ADVP (RB significantly)) (VBD reduced) (NP (NP (JJ colorectal) (NN cancer) (NN tissue) (NN cancer) (NN cell)) (, ,) (NP (JJ genetic) (NN deletion) (NN decorin) (NN gene) (JJ sufficient) (NN cause) (JJ intestinal) (NN tumor) (NN formation) (NN mouse)) (, ,) (VP (VBG resulting) (NP (NN downregulation) (NN p21))) (, ,) (NP (NP (NN p27)) (PRN (-LRB- -LRB-) (NP (NN kip1)) (-RRB- -RRB-))) (FRAG (NP (NN E-cadherin) (NN upregulation) (NN beta-catenin) (NN signaling)) (-LRB- -LSB-) (NP (NP (NN Bi)) (, ,) (NP (NN X))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 20:G03.495 23:D12.776.091.249 30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 69:G02.111.087.800 85:G02.111.087.225 98:A10 102:C04.588.274.476.411 249:G05.355.315.800 338:D12.644.360.225.600 339:G02.111.087.880 549:G05.355.600.800.320 708:D12.776.395.650.750.625 820:D12.776.395.550.200.200|ES| 2:1 7:1 9:1 10:1 14:1 17:1 18:1 19:1 43:1 52:1 60:1 94:1 109:1 115:1 124:1 131:1 195:1 237:1 242:1 272:1 384:1 452:1 595:1 864:1 929:1 1059:1 1124:1 1126:1 1135:1 1373:1 1779:1 2267:1 2900:1 2901:1 2902:1 2903:1
-1 	|BT| (S (S (NP (JJ Previous) (NN work)) (VP (VBD showed) (NP (NN loss) (NN TIP30)))) (, ,) (ADVP (RB also)) (VP (VBN called) (S (NP (NN CC3))) (, ,) (NP (NP (JJ putative) (NN tumor) (NN suppressor)) (, ,) (NP (VBD increased) (NN incidence) (JJ hepatocellular) (NN carcinoma) (NN mouse)) (, ,) (NP (JJ clinical) (NN sample) (JJ human) (NN HCC) (NN tissue) (JJ aberrant) (NN expression) (NN TIP30))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 55:B01.050.150.900.649.801.400.112.400.400 98:A10 104:C04.557.470.200.025.255 206:G05.360.340.024.340.375.249 434:E05.318.308.985.525.375 445:I03.946|ES| 2:1 5:1 7:1 19:1 32:1 36:1 47:1 52:1 84:1 115:1 132:1 272:1 303:1 304:1 441:1 700:1 835:1 918:1 1511:1 1546:1 1547:1 1725:1 2900:1 2904:1 2905:1
-1 	|BT| (S (NP (NNP Progastrin) (VBG targeting) (NN strategy)) (VP (VBP provide) (NP (JJ exciting) (NN prospect) (NN differentiation) (NN therapy) (JJ colorectal) (NN cancer)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 12:Z01.542.049 52:E02 74:G04.299.151 821:E05.318.760.500.750.500|ES| 17:1 18:1 19:1 130:1 215:1 616:1 711:1 1114:1 2906:1 2907:1 2908:1
1 	|BT| (NP (NP (NP (NN BACKGROUND)) (CC &) (NP (NNS AIMS))) (: :) (S (NP (NP (NN Androgen) (NN effect) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (VP (VBP remain) (SBAR (S (NP (JJ controversial) (NN androgen) (NN ablation) (NN therapy) (NN treat) (NNP HCC)) (ADVP (RB also)) (VP (VBP lead) (NP (JJ inconsistent) (NN result)))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 86:D01.268.556.435 104:C04.557.470.200.025.255 891:D27.505.696.399.472.161 892:D27.505.696.399.472.161|ES| 5:1 10:1 14:1 19:1 75:1 91:1 101:1 104:1 130:1 254:1 303:1 304:1 441:1 1046:1 1090:1 1777:1 1778:1 1852:1 2181:1 3153:1 3154:1 3155:1
1 	|BT| (NP (NP (NP (NP (NN BACKGROUND)) (CC &) (NP (NNS AIMS))) (: :) (NP (NP (NP (NN Chromodomain) (NN helicase/adenosine) (NN triphosphatase) (NN DNA) (NN binding) (NN protein)) (NP (ADJP (JJ 1-like) (-LRB- -LRB-) (NN CHD1L) (-RRB- -RRB-) (JJ SNF2-like)) (NN transcription) (NN factor))) (VP (VBN involved) (S (VP (NN development) (NP (NP (JJ human) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))))))) |ET| |BS|14:F01.525 104:C04.557.470.200.025.255 166:D12.776.930 893:D08.811.277.040.025 894:D08.811.277.040.025|ES| 4:1 10:1 14:1 19:1 35:1 36:1 104:1 185:1 303:1 304:1 441:1 487:1 666:1 774:1 1046:1 1487:1 1777:1 1778:1 3156:1 3157:1 3158:1 3159:1 3160:1 3161:1
1 	|BT| (NP (NP (NN BACKGROUND)) (: :) (S (NP (PRP It)) (VP (VBD suggested) (NP (NP (JJ altered) (NN iron) (NN metabolism) (NN liver) (NN tumor)) (, ,) (NP (VBN characterized) (JJ iron-deficient) (NN phenotype)) (, ,) (NP (NN importance) (NN tumor) (NN growth)))))) |ET| |BS|8:C04 45:G07.700.320.249 80:G05.695 515:C04.588.274.623 895:D01.490.600 896:D01.268.556.412 897:Z01.252.245.500.375 898:G03.495|ES| 2:1 7:1 19:1 102:1 104:1 236:1 693:1 836:1 925:1 985:1 1046:1 1327:1 1660:1 3162:1 3163:1 3164:1
1 	|BT| (NP (NP (NN BACKGROUND) (: :)) (S (NP (DT The) (NP (NN ErbB2/Her2/Neu) (NN receptor) (NN tyrosine) (NN kinase))) (VP (VBD amplified) (NP (ADJP (QP (RB approximately) (CD 30)) (NN %)) (JJ human) (NN breast) (NN cancer))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400|ES| 18:1 19:1 23:1 36:1 104:1 186:1 369:1 470:1 691:1 1046:1 1520:1 1843:1 2208:1 2341:1 3165:1
1 	|BT| (NP (NP (NP (NP (NN Dehydroepiandrosterone)) (PRN (-LRB- -LRB-) (NP (NN DHEA)) (-RRB- -RRB-))) (, ,) (NP (JJ major) (NN precursor) (NN androgen) (NN estrogen)) (, ,)) (NP (NP (JJ several) (JJ beneficial) (NN effect) (JJ immune) (NN system)) (, ,) (NP (NN memory) (NN function)) (, ,) (S (VP (VBG modulating) (NP (NP (NN effect) (NN diabetes)) (, ,) (NP (NN obesity)) (, ,) (NP (NN chemical) (NN carcinogenesis))))))) |ET| |BS|33:C04.697.098 564:C18.654.726.500 726:C18.452.394.750 740:D04.808.054.079.429.625 889:D27.505.696.399.472.277 892:D27.505.696.399.472.161 899:F02.463.425.540 900:A15.382|ES| 2:1 10:1 14:1 19:1 33:1 75:1 207:1 262:1 462:1 593:1 984:1 2009:1 2010:1 2124:1 2435:1 2633:1 3154:1 3166:1 3167:1 3168:1 3169:1 3170:1
1 	|BT| (NP (NP (NP (NP (JJ Dimethylarsinic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN DMA)) (-RRB- -RRB-))) (JJ major) (NN metabolite) (JJ inorganic) (JJ arsenical)) (, ,) (NP (ADJP (RB epidemiologically) (JJ significant)) (NN chemical) (NN relation) (NN liver) (NN cancer) (NN mammal))) |ET| |BS|901:B01.050.150.900.649 902:D02.691.088.100 903:D01.075|ES| 2:1 10:1 14:1 18:1 19:1 135:1 462:1 836:1 1275:1 1678:1 2124:1 3171:1 3172:1 3173:1 3174:1 3175:1 3176:1 3177:1
1 	|BT| (NP (NP (NP (NN Ethanol) (NN consumption) (NN cause) (JJ serious) (NN liver) (NN injury)) (PP (VBG including) (NP (NN cirrhosis) (JJ hepatocellular) (NN carcinoma))))) |ET| |BS|73:N05.715.350.200 104:C04.557.470.200.025.255 242:A03.620 357:C06.552.630 662:C23.550.355 904:F01.145.317.269|ES| 19:1 303:1 304:1 561:1 836:1 1199:1 1779:1 2387:1 2416:1 3178:1 3179:1
1 	|BT| (S (NP (NP (NP (NN Expression) (NN cyclooxygenase)) (PRN (-LRB- -LRB-) (NP (NN COX)) (-RRB- -RRB-))) (CD -2) (NN protein) (NN rat) (NN hepatocarcinogenesis)) (VP (VBN associated) (NP (NP (JJ fatty) (NN change)) (, ,) (NP (NN fibrosis)) (, ,)) (NP (NP (NN cirrhosis) (JJ oxidative) (NN DNA) (NN damage)) (, ,) (VP (VBD caused) (SBAR (S (NP (ADJP (ADJP (JJ choline-deficient)) (, ,) (ADJP (ADJP (NN L-amino) (JJ acid-defined)) (PRN (-LRB- -LRB-) (ADJP (JJ CDAA)) (-RRB- -RRB-)))) (NN diet)) (VP (VBD investigated) (NP (NP (NN F344) (JJ male) (NN rat)) (, ,) (PP (IN along) (NP (NP (JJ chemopreventive) (NN efficacy) (JJ specific) (NN COX-2) (NN inhibitor)) (, ,) (NP (NP (NN nimesulide)) (PRN (-LRB- -LRB-) (NP (NN NIM)) (-RRB- -RRB-))))))))))))) |ET| |BS|7:D12.776 24:D08.811.600.720.750 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 349:D27.505.519.389.310.500 357:C06.552.630 526:G05.355.180 590:B01.050.050.199.520.760.200 594:D02.033.100.291.211 595:G07.203.650.240 596:E02.642.249 597:D12.125 662:C23.550.355 691:C23.550.355|ES| 2:1 4:1 10:1 14:1 19:1 76:1 169:1 200:1 316:1 380:1 403:1 540:1 666:1 849:1 900:1 949:1 1199:1 1402:1 1848:1 1946:1 2070:1 2188:1 2190:1 2191:1 2304:1 2506:1 2583:1 2666:1 3180:1 3181:1 3182:1 3183:1 3184:1 3185:1 3186:1 3187:1
1 	|BT| (NP (NP (NNP Hepatitis) (NN B) (NN virus) (-LRB- -LRB-) (NN HBV) (-RRB- -RRB-) (: -)) (NP (VBN induced) (NN hepatitis) (NP (NP (JJ carcinogen-induced) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NP (JJ associated) (NN serum) (NN androgen) (NN concentration)))) |ET| |BS|104:C04.557.470.200.025.255 279:D27.888.569.100 782:A12.207.152.846 863:B04.280.375.650.425 892:D27.505.696.399.472.161 905:F02.830.104.214|ES| 10:1 14:1 19:1 169:1 303:1 304:1 409:1 441:1 763:1 1422:1 1954:1 2048:1 2421:1 2741:1 3154:1 3188:1 3189:1
1 	|BT| (S (PP (IN In) (NP (NN line) (NN observation))) (, ,) (NP (JJR lower) (NN serum) (NN level) (JJ active) (NN Caspase-3)) (VP (VBD found) (SBAR (S (NP (NN patient) (JJ metastasised) (NN CRC)) (VP (VBD revealed) (NP (NP (JJ stable) (NN disease) (NN tumour) (NN regression)) (VBN compared) (NN disease) (NN progression))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 16:C23.550.291.656 50:M01.643 288:C23.550.288 429:N04.761.559.590.900 430:E05.581.249 782:A12.207.152.846 846:F01.393.784 906:D08.811.277.656.262.500.126.350.300|ES| 2:1 19:1 37:1 48:1 50:1 117:1 120:1 197:1 244:1 245:1 249:1 264:1 275:1 360:1 998:1 1011:1 1477:1 2741:1 3002:1 3190:1 3191:1
1 	|BT| (S (PP (IN In) (NP (NN order))) (VB clarify) (SBAR (IN whether) (S (NP (NP (JJ peroxisomal) (NN hydrogen) (NN peroxide)) (PRN (-LRB- -LRB-) (NP (NN H2O2)) (-RRB- -RRB-))) (VP (VBP play) (NP (JJ important) (NN role) (NN peroxisome) (JJ proliferator-induced) (NN hepatocarcinogenesis))))) (, ,) (NP (VBN examined) (NN change) (NN metabolism) (JJ peroxisomal) (NN H2O2)) (ADVP (FW vivo) (FW vitro)) (VP (VBG using) (NP (NP (JJ male) (NN Fischer-344) (NN rat) (NN fed) (NN clofibrate)) (, ,) (NP (NP (JJ bezafibrate) (FW di)) (PRN (-LRB- -LRB-) (NP (NN 2-ethylhexyl)) (-RRB- -RRB-))) (NP (NP (NN phthalate)) (PRN (-LRB- -LRB-) (NP (NN DEHP)) (-RRB- -RRB-)))) (NP (CD 78) (NN week)))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 79:I03.450.642.693 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 479:G08.686.157.500 590:B01.050.050.199.520.760.200 663:C16.320.565.398.500.330.500 898:G03.495 907:D01.248.497.158.685.750.424 908:A11.284.430.214.190.500.585.600 909:D02.065.277.067 910:D02.241.081.114.968.500.500.195 911:D02.241.223.805.250 912:D27.888.569.100.675|ES| 2:1 10:1 14:1 19:1 31:1 200:1 216:1 221:1 238:1 244:1 324:1 350:1 378:1 783:1 849:1 900:1 902:1 1402:1 1887:1 2426:1 3163:1 3192:1 3193:1 3194:1 3195:1 3196:1 3197:1 3198:1 3199:1 3200:1 3201:1 3202:1 3203:1 3204:1 3205:1 3206:1
1 	|BT| (S (S (VP (VBG Mounting) (NP (NN evidence)))) (VP (VBP underline) (NP (NP (NP (NP (NP (NP (NN role) (JJ inducible) (JJ nitric) (NN oxide) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NN iNOS)) (-RRB- -RRB-))) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))) (NN development)) (, ,) (NP (JJ functional) (NN interaction) (NN pathway))) (VP (VBN involved) (NP (NNP HCC) (NN progression)))) (VP (VBP remain) (ADJP (JJ uninvestigated))))) |ET| |BS|15:F01.829.316.616 16:C23.550.291.656 22:D08.811.682.664.500.772.500 104:C04.557.470.200.025.255|ES| 2:1 10:1 14:1 19:1 31:1 35:1 38:1 48:1 63:1 64:1 65:1 66:1 67:1 303:1 304:1 383:1 415:1 441:1 618:1 774:1 2181:1 3207:1 3208:1 3209:1
1 	|BT| (S (NP (NNP Sorafenib) (NN increase) (NN survival) (NN rate) (NN patient)) (VP (VBD advanced) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))) |ET| |BS|50:M01.643 104:C04.557.470.200.025.255 779:E05.318.308.985.550.900|ES| 10:1 14:1 19:1 40:1 41:1 120:1 274:1 303:1 304:1 441:1 997:1 3210:1
1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (VP (VBP result) (VP (VBP suggest) (SBAR (S (NP (NN ADAM9)) (VP (VBZ contributes) (NP (NN pathogenesis) (NN prostate) (NN cancer)) (ADVP (RB potentially)) (ADVP (RB also)) (NP (NN carcinoma)) (, ,) (S (VP (VBG raising) (SBAR (S (NP (NN possibility) (NN ADAM9)) (VP (MD might) (NP (JJ good) (NN target) (NN antitumor) (NN drug))))))))))))) |ET| |BS|265:C04.557.470.200 369:E02.319.300|ES| 2:1 5:1 18:1 19:1 77:1 101:1 160:1 191:1 304:1 343:1 501:1 773:1 796:1 798:1 845:1 1318:1 1537:1 1538:1 2244:1 3211:1 3212:1
1 	|BT| (S (NP (DT The) (NN purpose) (NN investigation)) (VP (VB evaluate) (NP (NP (JJ possible) (NN influence) (NN mixture) (NN pesticide) (JJ medium-term) (NN carcinogenesis)) (VP (VBG using) (NP (VBN improved) (NN hepatocarcinogenesis) (NN protocol)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 225:E05.337 826:F01.752.609 849:G08.686.785.760.769.490.500 913:D27.720.031.700 914:L01.178|ES| 19:1 207:1 350:1 691:1 867:1 890:1 900:1 1359:1 1497:1 2410:1 3011:1 3213:1 3214:1 3215:1 3216:1
1 	|BT| (S (NP (EX There)) (VP (VBG increasing) (NP (NN interest) (NP (NP (NNS phytoestrogens) (JJ potential) (JJ alternative) (JJ synthetic) (JJ selective) (NN estrogen) (NN receptor) (NNS modulators)) (PRN (-LRB- -LRB-) (NP (NNS SERMs)) (-RRB- -RRB-))) (NN prevention) (NN therapy) (NN breast) (NN cancer)))) |ET| |BS|52:E02 375:Z01.639.100 831:D27.505.696.399.472.277.540.500 915:D06.347.360.827|ES| 10:1 14:1 18:1 19:1 23:1 130:1 186:1 715:1 827:1 1474:1 1749:1 2311:1 2671:1 2955:1 3168:1 3217:1 3218:1 3219:1 3220:1
1 	|BT| (NP (NP (S (VP (TO To) (VP (VB clarify) (S (VP (VBG modifying) (NP (NP (NN effect) (NN N-Acetyl-L-Cysteine)) (PRN (-LRB- -LRB-) (NP (NN NAC)) (-RRB- -RRB-)))))))) (, ,) (NP (NP (JJ antioxidative) (NN ability)) (, ,) (NP (NN hepatocarcinogenesis)) (VP (VBD promoted) (SBAR (S (NP (NP (NP (NP (NN fenofibrate)) (PRN (-LRB- -LRB-) (NP (NN FF)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NN peroxisome) (JJ proliferator-activated) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN PPAR)) (-RRB- -RRB-))) (NN alpha)) (NP (NN agonist))) (, ,) (NP (NP (JJ male) (NN F344/N) (NN rat)) (VP (VBN administered) (NP (NP (NP (ADJP (JJ single) (JJ intraperitoneal)) (NN injection) (NN N-diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (NN initiator))))) (VP (VBD followed) (NP (NN administration) (NN diet) (VBG containing) (CD 3,000) (NN ppm) (NN FF) (CD 16) (NN week))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 385:F02.784.629.131 536:D12.776.826.239.500 554:D02.654.442.200 590:B01.050.050.199.520.760.200 596:E02.642.249 791:D02.886.030.230.259 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725 916:D02.241.081.114.968.500.625 917:E02.319.267.530.490|ES| 2:1 10:1 14:1 19:1 75:1 186:1 286:1 783:1 785:1 828:1 849:1 900:1 1300:1 1402:1 1801:1 1836:1 1875:1 1887:1 1912:1 2191:1 2336:1 2575:1 2644:1 2846:1 3130:1 3193:1 3221:1 3222:1 3223:1 3224:1 3225:1 3226:1 3227:1 3228:1 3229:1 3230:1 3231:1 3232:1 3233:1 3234:1
1 	|BT| (NP (NP (NP (NNP UNLABELLED) (: :) (NN Activation) (NN beta-catenin)) (, ,) (NP (NP (JJ central) (NN effector) (JJ canonical) (NN Wnt) (NN pathway)) (VP (VBD recognized) (NP (NP (NN oncogene)) (, ,) (NP (VBN implicated) (JJ hepatocellular) (NN carcinoma))))))) |ET| |BS|9:G05.360.340.024.340.375.500 23:D12.776.091.249 104:C04.557.470.200.025.255 105:G02.149.115.800.925|ES| 2:1 19:1 24:1 60:1 87:1 104:1 303:1 304:1 383:1 570:1 877:1 977:1 2266:1 3235:1 3236:1 3237:1
1 	|BT| (NP (NP (NP (NNP UNLABELLED)) (: :) (NP (NP (NP (JJ Antidiabetic) (NNS thiazolidinediones)) (PRN (-LRB- -LRB-) (NP (NN TZD)) (-RRB- -RRB-))) (PP (FW vitro) (NP (NP (JJ antiproliferative) (NN effect) (JJ epithelial) (NN cancer)) (, ,) (PP (VBG including) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))))))) |ET| |BS|104:C04.557.470.200.025.255 862:D02.886.675.933 878:D27.505.696.422|ES| 2:1 10:1 14:1 18:1 19:1 75:1 104:1 127:1 216:1 303:1 304:1 441:1 561:1 2266:1 3117:1 3118:1 3119:1 3120:1
1 	|BT| (NP (NP (NP (NNP UNLABELLED)) (: :) (NP (NP (DT The) (NN Wnt/beta-catenin) (NN pathway)) (VP (VBN implicated) (NP (NP (NN pathogenesis) (JJ hepatocellular) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))))) |ET| |BS|23:D12.776.091.249 147:G02.149.115.800.925|ES| 10:1 14:1 18:1 19:1 104:1 302:1 303:1 383:1 441:1 501:1 691:1 977:1 2266:1
1 	|BT| (S (NP (NN 17-Allylamino-17-demethoxygeldanamycin)) (VP (VBZ overcomes) (NP (NN TRAIL) (NN resistance) (NN colon) (NN cancer) (NN cell) (NN line)))) |ET| |BS|94:A11.251.210|ES| 18:1 19:1 94:1 113:1 264:1 1094:1 1695:1 3238:1 3239:1
1 	|BT| (S (NP (NN 5-Lipoxygenase)) (VP (VBZ contributes) (NP (NN progression) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|16:C23.550.291.656 104:C04.557.470.200.025.255 918:D08.811.682.690.416.583.500.055|ES| 19:1 48:1 303:1 304:1 845:1 3240:1
1 	|BT| (S (NP (DT A) (JJ novel) (JJ CYR61-triggered) (`` `) (NN CYR61-alphavbeta3) (NN integrin) (NN loop)) ('' ') (VP (VBZ regulates) (NP (NN breast) (NN cancer) (NN cell) (NN survival) (NN chemosensitivity) (NN activation) (NN ERK1/ERK2) (NN MAPK) (NN signaling) (NN pathway)))) |ET| |BS|69:G02.111.087.800 108:G04.299.316 116:D08.811.913.696.620.682.700.567.249.750 126:G02.111.087.800 259:D12.776.395.240.150.500 573:N05.715.350.200.650 919:D08.811.913.696.620.682.700.567.249.500 920:D12.776.543.750.705.408|ES| 18:1 19:1 23:1 69:1 94:1 195:1 225:1 248:1 274:1 383:1 386:1 603:1 809:1 891:1 1489:1 3241:1 3242:1 3243:1 3244:1
1 	|BT| (NP (NP (NP (DT A) (JJ novel) (NN inhibitor) (JJ fatty) (NN acid) (NN synthase) (NN show) (NN activity) (NN HER2)) (CC +) (NP (NN breast) (NN cancer) (NN xenograft) (JJ active) (JJ anti-HER2) (JJ drug-resistant) (NN cell) (NN line)))) |ET| |BS|63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 67:D26 92:E04.936.764 93:A01.941.875 94:A11.251.210 259:D12.776.395.240.150.500 921:D08.811.682.664.500.772 922:D10.251|ES| 18:1 19:1 23:1 66:1 69:1 94:1 197:1 264:1 265:1 380:1 399:1 429:1 891:1 1275:1 2070:1 3245:1 3246:1 3247:1
1 	|BT| (S (NP (DT A) (NP (JJ pivotal) (NN signaling) (NN network) (JJ colorectal) (NN cancer) (NN cell))) (VP (VBZ involves) (NP (NP (NP (NN glycogen) (NN synthase) (NN kinase-3beta)) (PRN (-LRB- -LRB-) (NP (NN GSK3beta)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ multifunctional) (NN kinase)) (SBAR (WHNP (WP$ whose) (NN role) (NN tumor) (NN cell) (NN survival)) (S (VP (VBN defined)))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 15:F01.829.316.616 69:G02.111.087.800 108:G04.299.316 469:D08.811.913.696 588:I01.880.853.500.600|ES| 2:1 7:1 10:1 14:1 17:1 18:1 19:1 31:1 66:1 69:1 92:1 93:1 94:1 195:1 274:1 470:1 680:1 919:1 1673:1 1878:1 1894:1 2154:1 3248:1
1 	|BT| (S (S (NP (DT A) (JJ potential) (VBG underlying) (NN mechanism) (NN role) (NN ADAM9) (NN prostate) (NN cancer)) (VP (VBD emerged) (NP (JJ cell-based) (NN assay)))) (: :) (S (NP (NN ADAM9)) (VP (VBP cleave) (NP (NP (NN release) (JJ epidermal) (NN growth) (NN factor) (NN FGFR2iiib) (NN cell)) (, ,) (NP (JJ pivotal) (NN function) (NN pathogenesis) (NN disease)))))) |ET| |BS|15:F01.829.316.616 41:A11 106:E05.091 288:C23.550.288 333:D01.045 589:E02.204.125 923:D06.472.317.350|ES| 2:1 18:1 19:1 31:1 33:1 69:1 77:1 94:1 102:1 104:1 162:1 184:1 185:1 310:1 435:1 501:1 827:1 998:1 1113:1 2165:1 3211:1 3248:1 3249:1 3250:1 3251:1
1 	|BT| (S (NP (JJ Aberrant) (NN beta-catenin) (JJ intracellular) (NN distribution)) (VP (VBD found) (NP (NP (JJ gastric) (NP (NN cancer)) (, ,) (NP (NN pattern) (NN Wnt) (NN expression) (JJ stepwise) (NN gastrocarcinogenesis) (JJ potential) (NN influence) (NN beta-catenin) (NN distribution)) (ADJP (RB still) (JJR lesser))) (VP (VBN known))))) |ET| |BS|23:D12.776.091.249 826:F01.752.609 924:A11.284.430.214|ES| 2:1 18:1 19:1 37:1 60:1 80:1 86:1 115:1 260:1 556:1 776:1 827:1 867:1 877:1 2805:1 3252:1 3253:1 3254:1 3255:1
1 	|BT| (NP (NP (JJ Aberrant) (NN methylation) (NN histone) (NN deacetylation) (NN cyclooxygenase) (CD 2) (JJ gastric) (NN cancer))) |ET| |BS|24:D08.811.600.720.750 36:G02.111.087.029.538 399:D12.776.660.470|ES| 18:1 19:1 80:1 81:1 86:1 148:1 503:1 3180:1 3256:1
1 	|BT| (S (NP (ADJP (QP (IN About) (CD 80)) (NN %)) (JJ gastric) (NN cancer)) (VP (VBD showed) (NP (JJ high) (NN level) (NN expression) (NN cyclooxygenase) (CD 2)) (, ,) (S (NP (NN subset) (NN case)) (VP (VBP express) (PP (IN without) (NP (JJ unknown) (NN reason))))))) |ET| |BS|24:D08.811.600.720.750|ES| 2:1 18:1 19:1 86:1 115:1 132:1 148:1 178:1 208:1 249:1 369:1 573:1 934:1 1195:1 1285:1 2182:1 3180:1 3257:1 3258:1
1 	|BT| (S (NP (VBN Accelerated) (NN liver) (NN regeneration) (NN hepatocarcinogenesis) (NN mouse)) (VP (VBG overexpressing) (NP (NN serine-45) (JJ mutant) (NN beta-catenin)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 23:D12.776.091.249 925:G10.261.326.520 926:D12.125.154.800|ES| 19:1 52:1 60:1 811:1 836:1 900:1 3259:1 3260:1 3261:1 3262:1
1 	|BT| (S (NP (NN Acylglycerol) (NN kinase)) (VP (VBZ promotes) (NP (NN cell) (NN proliferation) (NN tumorigenicity) (NN breast) (NN cancer)) (PP (IN via) (NP (NN suppression) (NN FOXO1) (NN transcription) (NN factor))))) |ET| |BS|183:G04.299.233.750 209:G02.111.087.847|ES| 18:1 19:1 23:1 94:1 185:1 298:1 299:1 300:1 470:1 487:1 596:1 2453:1 3263:1 3264:1
1 	|BT| (S (PP (IN After) (NP (JJ 2-week) (NN treatment))) (, ,) (NP (NN animal)) (VP (VBN subjected) (SBAR (`` ``) (S (NP (NP (JJ resistant) (NN hepatocyte) ('' '') (NN model) (NN hepatocarcinogenesis)) (PRN (-LRB- -LRB-) (NP (NP (NN initiation) (NN diethylnitrosamine)) (, ,) (NP (NN selection/promotion) (JJ 2-acetylaminofluorene) (JJ partial) (NN hepatectomy))) (-RRB- -RRB-))) (VP (VBD euthanized) (NP (ADJP (CD 8) (NN week)) (NN treatment))))))) |ET| |BS|19:B01.050 52:E02 262:A11.436.348 554:D02.654.442.200 812:G05.355.800 881:D02.065.064.150 927:E02.760.905.850 928:E04.210.556|ES| 2:1 10:1 14:1 19:1 46:1 72:1 427:1 546:1 637:1 781:1 783:1 900:1 1909:1 1952:1 3265:1 3266:1 3267:1 3268:1 3269:1 3270:1 3271:1 3272:1 3273:1 3274:1
1 	|BT| (S (NP (NP (NP (JJ Aldo-keto) (NN reductase) (NN family) (CD 1) (NN B10)) (PRN (-LRB- -LRB-) (NP (NN AKR1B10)) (-RRB- -RRB-))) (, ,) (NP (NN member) (JJ aldo-keto) (NN reductase) (NN superfamily)) (, ,)) (VP (VP (VBN overexpressed) (NP (JJ human) (JJ hepatocellular) (NN carcinoma))) (, ,) (NP (NN lung) (JJ squamous) (NN cell) (NN carcinoma) (NN lung) (NN adenocarcinoma)))) |ET| |BS|44:F01.829.263 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 182:A04.411 929:C04.557.470.200.400|ES| 2:1 10:1 14:1 19:1 25:1 36:1 94:1 95:1 96:1 97:1 98:1 99:1 255:1 303:1 304:1 328:1 769:1 1067:1 3275:1 3276:1 3277:1
1 	|BT| (S (NP (DT All) (NN result)) (VP (VBP suggest) (SBAR (S (NP (JJ low) (NN concentration) (NN acrylamide)) (VP (MD may) (VP (VB contribute) (NP (NP (NN progression) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))))))) |ET| |BS|16:C23.550.291.656 104:C04.557.470.200.025.255 905:F02.830.104.214 930:D02.065.122.015|ES| 10:1 14:1 19:1 48:1 101:1 303:1 304:1 441:1 450:1 491:1 531:1 796:1 965:1 3189:1 3278:1
1 	|BT| (FRAG (SBAR (IN Although) (S (VP (ADVP (RB spontaneously)) (VB develop) (NP (NP (NN liver) (NN tumor)) (, ,) (NP (NN IL-22TG) (NN mouse) (JJ susceptible) (JJ diethylnitrosamine-induced) (NN liver) (NN cancer))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 515:C04.588.274.623 554:D02.654.442.200 897:Z01.252.245.500.375 931:Z01.107.567.875.350.350 932:D12.644.276.374.465|ES| 2:1 7:1 18:1 19:1 52:1 107:1 648:1 836:1 899:1 1506:1 2732:1 3279:1
1 	|BT| (S (IN Although) (, ,) (NP (NP (NN NLK) (VBN known) (NN tumor) (NN suppressor) (NN Wnt/beta-catenin) (NN signaling) (NN pathway) (NN colon) (NN cancer)) (, ,) (NP (NN event) (VBG occurring) (NP (JJ downstream) (NN NLK) (NN pathway) (NN type) (NN cancer)))) (VP (VBP remain) (ADJP (JJ unclear)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 105:G02.149.115.800.925 206:G05.360.340.024.340.375.249|ES| 2:1 7:1 18:1 19:1 107:1 113:1 195:1 205:1 302:1 383:1 443:1 543:1 556:1 560:1 700:1 1737:1 2181:1 3280:1
1 	|BT| (NP (NP (PP (IN Among) (NP (NNS others))) (, ,) (NP (NN bladder) (, ,) (NN lung) (, ,) (NN colon) (, ,) (NN breast) (NN cancer) (VBN associated) (NN 4-ABP)))) |ET| |BS|46:A03.556.124.526.356 182:A04.411 933:A05.810.890|ES| 2:1 18:1 19:1 23:1 113:1 169:1 328:1 564:1 1000:1 3281:1 3282:1
